Companies › Unlimited Biotechnology
2 active drug programs in 2 registered trials: 2 Phase 1; Other; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AAV9-Follistatin gene therapy Adeno-associated virus serotype 9 vector encoding human follistatin to increase muscle mas | FST | Phase 1 | Age-related Muscle Decline | Sep 2027 |
| VEGF Plasmid Intramuscular plasmid DNA encoding vascular endothelial growth factor to induce angiogenes | VEGFA | Phase 1 | Age-related Muscle Decline | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07443826 | AAV9-Follistatin gene therapy | Phase 1 | Age-related Muscle Decline | Other | Sep 2027 |
| NCT07443826 | VEGF Plasmid | Phase 1 | Age-related Muscle Decline | Other | Sep 2027 |
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.